Cencora EVP Elizabeth Campbell sells $1.1 million in stock

Published 26/03/2025, 21:40
Cencora EVP Elizabeth Campbell sells $1.1 million in stock

Elizabeth S. Campbell, Executive Vice President at Cencora, Inc. (NYSE:COR), recently sold a total of 4,127 shares of the company’s common stock. The transactions, which took place on March 24, were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 19, 2024. The sale comes as Cencora, a prominent player in the Healthcare Providers & Services industry with a market capitalization of $52.7 billion, trades near its 52-week high of $271.07.

The shares were sold at a price of $268.28 each, resulting in a total transaction value of approximately $1,107,191. Following these sales, Campbell retains ownership of 14,664.53 shares in the company. The stock has shown strong momentum, delivering a 20.5% return over the past six months, while maintaining a 20-year streak of dividend increases.

These transactions are part of regular trading activities and provide a window into the personal financial management strategies of Cencora’s executive team. Investors often monitor such sales to gauge insider sentiment about the company’s stock performance. With an "GOOD" overall Financial Health Score and analysts maintaining a bullish consensus, the stock appears well-positioned. For deeper insights into insider trading patterns and comprehensive analysis, InvestingPro subscribers can access detailed reports and real-time alerts.

In other recent news, Cencora, Inc. has raised its fiscal year 2025 adjusted earnings per share (EPS) guidance following the acquisition of Retina Consultants of America. The transaction was completed for $4.4 billion, with Cencora acquiring an 85% stake in the company. As a result, the EPS guidance has been increased to a range of $15.15 to $15.45, up from the previous estimate of $14.80 to $15.10. Additionally, Leerink Partners has raised Cencora’s stock price target to $301 while maintaining an Outperform rating, citing strong first-quarter results and robust performance in the U.S. Healthcare segment.

In another development, Cencora’s shareholders have approved executive compensation and elected directors at the recent Annual Meeting. The meeting also saw the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year 2025. Meanwhile, Cencora announced the upcoming retirements of board members Richard W. Gochnauer and Kathleen W. Hyle, set to occur at the next Annual Meeting. These changes will reduce the board from 13 to 11 members.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.